|1.||Chandra, Subhash: 4 articles (06/2014 - 08/2002)|
|2.||Kabalka, George W: 4 articles (06/2014 - 08/2002)|
|3.||Coderre, J A: 4 articles (11/2004 - 04/2001)|
|4.||Chandra, S: 3 articles (06/2014 - 11/2001)|
|5.||Shaikh, Aarif L: 3 articles (06/2014 - 12/2011)|
|6.||Barth, R F: 3 articles (06/2014 - 11/2001)|
|7.||Huo, Tianyao: 3 articles (06/2014 - 12/2011)|
|8.||Yang, Weilian: 3 articles (06/2014 - 12/2011)|
|9.||Barth, Rolf F: 3 articles (06/2014 - 12/2011)|
|10.||Wittig, Andrea: 3 articles (10/2009 - 07/2008)|
|1.||Melanoma (Melanoma, Malignant)
09/01/1996 - "Cellular effect of thermal neutron capture treatment using 10B1-para-boronophenylalanine: lethal effect on melanoma cells with different degrees of X-ray sensitivity."
02/01/1992 - "Tissue distribution of para-boronophenylalanine administered orally as a cyclodextrin inclusion complex to melanoma-bearing hamsters."
12/01/1987 - "in BALB/c mice, we have demonstrated that p-boronophenylalanine (BPA) is taken up by melanoma tissue to a much greater extent than by normal tissues. "
02/01/1992 - "Boron neutron capture therapy of anterior chamber melanoma with p-boronophenylalanine."
11/01/1991 - "Boron neutron capture therapy of a murine melanoma with p-boronophenylalanine: dose-response analysis using a morbidity index."
09/01/2006 - "We confirmed the p-boronophenylalanine (BPA)-accumulating capacity of the tumor by fluorine-18-labeled p-boronophenylalanine positron emission tomography ((18)F-BPA PET) before BNCT. "
03/30/1994 - "To study the biodistribution of p-Boronophenylalanine in patients undergoing surgery for intracranial tumors or metastatic melanoma. "
03/01/2013 - "Effect of bevacizumab treatment on p-boronophenylalanine distribution in murine tumor."
03/01/2003 - "The two drugs that have been used clinically, p-boronophenylalanine, (BPA), and the sulfhydryl borane, (BSH), seem to be taken up preferentially in solid tumor areas but it is uncertain whether enough boron is taken up by micro-invasive tumor cells. "
03/01/1996 - "Compounds developed for targeting to tumors include borocaptate sodium (BSH) and p-boronophenylalanine (BPA) which are currently in clinical use. "
06/01/2014 - "The first, L-p-boronophenylalanine (BPA), has been used clinically for BNCT of high-grade gliomas, recurrent tumours of the head and neck region and melanomas. "
11/15/2001 - "Ion microscopy was used to evaluate the microdistribution of boron-10 from p-boronophenylalanine (BPA) in the 9L rat gliosarcoma and the F98 rat glioma brain tumor models. "
02/01/2004 - "L-p-Boronophenylalanine (BPA) has been applied as a potential boron carrier for the treatment of malignant glioma in clinical boron neutron capture therapy (BNCT) since 1994. "
01/01/2013 - "The significant improvement in boron uptake by both the main tumor mass and infiltrating tumor cells compared to those reported in animal and clinical studies of p-boronophenylalanine strongly suggest that cis-ABCPC has the potential to become a novel new boron delivery agent for neutron capture therapy of gliomas and melanomas."
|4.||Thyroid Neoplasms (Thyroid Cancer)
03/01/2005 - "In previous studies we have shown the selective uptake of p-boronophenylalanine (BPA) by undifferentiated thyroid cancer cells in vitro and in vivo, as well as the histologic cure of 50% of the nude mice transplanted with human UTC cells when treated with BPA and an appropriate neutron beam. "
11/15/2007 - "To analyze the possible increase in efficacy of boron neutron capture therapy (BNCT) for undifferentiated thyroid carcinoma (UTC) by using p-boronophenylalanine (BPA) plus 2,4-bis (alpha,beta-dihydroxyethyl)-deutero-porphyrin IX (BOPP) and BPA plus nicotinamide (NA) as a radiosensitizer of the BNCT reaction. "
|5.||Glioblastoma (Glioblastoma Multiforme)
02/01/1999 - "Clinical trials of boron neutron capture therapy (BNCT) for glioblastoma multiforme are currently in progress using p-boronophenylalanine (BPA) as the 10B delivery agent. "
05/01/1997 - "Boron neutron capture therapy for glioblastoma multiforme using p-boronophenylalanine and epithermal neutrons: trial design and early clinical results."
03/01/1998 - "Biodistribution of p-boronophenylalanine in patients with glioblastoma multiforme for use in boron neutron capture therapy."
05/01/1997 - "A Phase I/II clinical trial of boron neutron capture therapy (BNCT) for glioblastoma multiforme is underway using the amino acid analog p-boronophenylalanine (BPA) and the epithermal neutron beam at the Brook-haven Medical Research Reactor. "
02/01/1998 - "Boron-10 (10B) concentrations were measured in 107 surgical samples from 15 patients with glioblastoma multiforme who were infused with 95 atom% 10B-enriched p-boronophenylalanine (BPA) intravenously for 2 h just prior to surgery at doses ranging from 98 to 290 mg BPA/kg body weight. "
|4.||DNA (Deoxyribonucleic Acid)
|7.||mercaptoundecahydrododecaborate (borocaptate sodium)
|9.||Dosage Forms (Dosage Form)
|1.||Boron Neutron Capture Therapy
|2.||Neutron Capture Therapy
|4.||Heterologous Transplantation (Xenotransplantation)